MBOAT7 and metabolic dysfunction-associated steatotic liver disease: For example, the common PNPLA3 p.I148M, MBOAT7 p.G17E, and TM6SF2 p.E167K variants have been shown to increase the risk of liver steatosis, fibrosis, and cirrhosis in patients with nonalcoholic fatty liver disease (NAFLD), alcoholic liver disease (ALD), and with viral liver diseases3–6.